STOCK TITAN

Eikon Therapeutics (EIKN) 424B Filings

EIKN NASDAQ

Here are the 424B prospectus supplements from Eikon Therapeutics, Inc. (EIKN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow EIKN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EIKN filings page.

Rhea-AI Summary

Eikon Therapeutics, Inc. is conducting an initial public offering of 21,177,600 shares of common stock at $18.00 per share, for a stated gross offering amount of $381,196,800 and estimated net proceeds to the company, before expenses, of $354,513,024. Underwriters have a 30‑day option to buy up to 3,176,640 additional shares at the same price, less underwriting discounts and commissions. The stock is approved for listing on the Nasdaq Global Select Market under the symbol “EIKN.”

Eikon is a late‑stage clinical biopharmaceutical company focused on oncology, with multiple product candidates in Phase 1/2 and Phase 2/3 trials, including toll‑like receptor and selective PARP1 inhibitors, a WRN helicase inhibitor, and androgen receptor programs. The company estimates cash, cash equivalents and short‑term investments of approximately $336.0 million as of December 31, 2025, but has reported recurring net losses of about $244.6 million for the nine months ended September 30, 2025 and an accumulated deficit of $840.9 million. Its own analysis notes substantial doubt about its ability to continue as a going concern without raising additional capital.